Drug survival of biologic treatments in psoriasis: a systematic review
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug survival of biologic treatments in psoriasis: a systematic review
Authors
Keywords
-
Journal
JOURNAL OF DERMATOLOGICAL TREATMENT
Volume 29, Issue 5, Pages 460-466
Publisher
Informa UK Limited
Online
2017-10-28
DOI
10.1080/09546634.2017.1398393
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria
- (2016) M Inzinger et al. ACTA DERMATO-VENEREOLOGICA
- Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
- (2016) Peter C.M. van de Kerkhof et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Persistence and failure rates of adalimumab monotherapy in biologic-naïve patients with psoriasis: A retrospective study
- (2016) Shivani P. Reddy et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice
- (2016) Eva Vilarrasa et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
- (2016) A. Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment Patterns and Annual Drug Costs of Biologic Therapies Across Indications from the Humana Commercial Database
- (2016) Andrew Howe et al. JOURNAL OF MANAGED CARE PHARMACY
- Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective
- (2015) Christopher Ross et al. AUSTRALASIAN JOURNAL OF DERMATOLOGY
- Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
- (2015) R.G. Langley et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis
- (2015) Lluís Puig et al. DERMATOLOGY
- Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis
- (2015) Arnd Jacobi et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes
- (2015) Denis Jullien et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
- (2015) Richard B. Warren et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study
- (2015) Whan B. Kim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results
- (2015) Alexa B. Kimball et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis
- (2015) Robert E. Kalb et al. JAMA Dermatology
- Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis
- (2015) Steven R. Feldman et al. Journal of Managed Care & Specialty Pharmacy
- Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice
- (2014) N.H. Shear et al. BRITISH JOURNAL OF DERMATOLOGY
- ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
- (2014) J.M.P.A. van den Reek et al. BRITISH JOURNAL OF DERMATOLOGY
- Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis
- (2014) S.P. Menting et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris
- (2014) R. Gniadecki et al. BRITISH JOURNAL OF DERMATOLOGY
- What Happened after the Clinical Trials: Long-Term Safety and Efficacy of Ustekinumab in Daily Clinical Practice
- (2014) Marina Talamonti et al. DERMATOLOGY
- Long-term durability and dose escalation patterns in infliximab therapy for psoriasis
- (2014) Adam J. Luber et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Clinical relevance of immunogenicity of biologics in psoriasis: Implications for treatment strategies
- (2014) J.-M. Carrascosa et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study
- (2013) M. Esposito et al. BRITISH JOURNAL OF DERMATOLOGY
- Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre
- (2013) A. López-Ferrer et al. BRITISH JOURNAL OF DERMATOLOGY
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis
- (2013) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Antidrug antibodies in psoriasis: a systematic review
- (2013) L. Hsu et al. BRITISH JOURNAL OF DERMATOLOGY
- Biologic fatigue in psoriasis
- (2013) Ethan C. Levin et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world setting
- (2013) Machaon Bonafede et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Drug survival rates in patients with psoriasis after treatment with biologics
- (2013) Yoshinori Umezawa et al. JOURNAL OF DERMATOLOGY
- OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis
- (2013) Alexa B. Kimball et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions
- (2013) J. Spertino et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis
- (2012) A.B. Gottlieb et al. BRITISH JOURNAL OF DERMATOLOGY
- Effect of dosing frequency on chronic cardiovascular disease medication adherence
- (2012) Craig I. Coleman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis
- (2012) Hidetoshi Takahashi et al. JOURNAL OF DERMATOLOGY
- Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice
- (2012) Paula P.M. van Lümig et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
- (2012) A.B. Kimball et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Drug survival rates of biologic treatments in patients with psoriasis vulgaris
- (2011) A.M.G. Brunasso et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)
- (2011) Tsen-Fang Tsai et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis
- (2011) Vito Di Lernia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial
- (2011) Atsuyuki IGARASHI et al. JOURNAL OF DERMATOLOGY
- Safety of treatment with biologics for psoriasis in daily practice: 5-year data
- (2011) P.P.M. van Lümig et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
- (2010) Akihiko ASAHINA et al. JOURNAL OF DERMATOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis
- (2010) Sarah Thayer et al. JOURNAL OF MEDICAL ECONOMICS
- Evaluation and Management of Psoriasis: An Internist's Guide
- (2009) Danielle Levine et al. MEDICAL CLINICS OF NORTH AMERICA
- Guidelines of care for the management of psoriasis and psoriatic arthritis
- (2008) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
- (2007) Alan Menter et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started